Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (Alpha1-Proteinase Inhibitor (Human), Intravenous)

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 1, 2014, Pages 17-25

  Sandhaus, Robert A ^a   Stocks, James ^b   Rouhani, Farshid N ^c   Brantly, Mark ^c   Strauss, Pnina ^d  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT TYLER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Kamada Ltd   (Israel)

Author keywords

Alpha 1 proteinase inhibitor deficiency; Augmentation therapy; Emphysema; Proteinase inhibition

Indexed keywords

ALPHA 1 ANTITRYPSIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GLASSIA; MONOMER; PROLASTIN C; UNCLASSIFIED DRUG;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG PURITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOGENICITY; JOINT SWELLING; LETHARGY; LIQUID; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SORE THROAT; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; TREATMENT OUTCOME;

EID: 84893341243     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.804500     Document Type: Article

References (32)

1. Eriksson S. Alpha 1-antitrypsin defi ciency: lessons learned from the bedside to the gene and back again. Chest 1989; 95:181-189.
2. Tobin MJ, Cook PJ, Hutchinson DC. Alpha 1 antitrypsin defi ciency: the clinical and physiological features of pulmonary emphysema in patients homozygous for Pi type Z. A survey by the British Th oracic Association. Br J Dis Chest 1983; 77(1):14-27.
3. American Th oracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin defi ciency. Am J Respir Crit Care Med 2003; 168:818-900.
4. Cole RB, Nevin NC, Blundell G, et al. Relation of alpha-1- antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population. Thorax 1976; 31(2):149-157.
5. Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha-1antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006; 173:1222- 1228.
6. Sandhaus RA. Elastase may play a central role in the neutrophil migration through connective tissue. In: Taylor JC, Mittman C, eds. Pulmonary emphysema and proteolysis. Orlando, FL: Academic Press, 1997:227-233.
7. de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin defi ciency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122(5): 1818-1829.
8. World Health Organization. Alpha-1-antitrypsin defi ciency. Memorandum from a WHO meeting. Bull WHO 1997; 75:397-415.
9. Dickens JA, Lomas DA. Why has it been so diffi cult to prove the effi cacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011; 5:391-405.
10. Stoller JK, Aboussouan LS. Alpha1-antitrypsin defi ciency. Lancet 2005; 365(9478):2225-2236.
11. Stolk J, Seersholm N, Kalsheker N. Alpha-1-antitrypsin defi ciency: current perspective on research, diagnosis, and management. Int J COPD 2006; 1(2):151-160.
12. Silverman EK, Sandhaus RA. Clinical practice. Alpha1- antitrypsin defi ciency. N Engl J Med 2009 Jun 25; 360(26):2749- 2757.
13. Sandhaus RA. Augmentation therapy in alpha-1 antitrypsin defi ciency. COPD J 2009 Jun; 6(3):147-148.
14. Petrache I, Hajjar J, Campos M. Safety and effi cacy of alpha- 1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin defi ciency. Biologics 2009; 3:193-204.
15. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin defi ciency associated with emphysema. N Engl J Med 1987; 316(17):1055-1062.
16. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin defi ciency: a meta-analysis. COPD J 2009 Jun; 6(3):177-184.
17. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010 Oct 5; 11:136.
18. Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha- 1-antitrypsin augmentation therapy in defi cient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009; 4:443-452.
19. Sandhaus RA. Alpha-1 antitrypsin defi ciency: whom to test, whom to treat? Semin Respir Crit Care Med 2010 Jun; 31(3):343-347.
20. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin defi ciency and lung disease. Cochrane Database Syst Rev 2010a Jul 7; (7):CD007851.
21. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Dan Med Bull 2010b Sep; 57(9):A4175.
22. Russi EW. Alpha-1 antitrypsin: now available, but do we need it? Swiss Med Wkly 2008; 138(13-14):191-196.
23. Abboud RT, Ford GT, Chapman KR; Standards Committee of the Canadian Th oracic Society. Alpha1-antitrypsin defi ciency: a position statement of the Canadian Th oracic Society. Can Respir J 2001; 8(2):81-88.
24. ARALAST NP Prescribing Information. Baxter Healthcare Corporation. Westlakes Village, CA, 2010. http://www.baxter. com/downloads/healthcare- professionals/products/Aralast- NP-PI.pdf
25. Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, et al. Pharmacokinetic comparability of ROLASTIN®-C to PROLASTIN?in alpha1-antitrypsin defi ciency: a randomized study. BMC Clin Pharmacol 2010; 10:13.
26. Stoller JK, Rouhani F, Brantly M, et al. Biochemical effi cacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 2002; 122:66-74.
27. Louie SG, Sclar DA, Gill MA. ARALAST: a new alpha1- protease inhibitor for treatment of alpha-antitrypsin defi ciency. Ann Pharmacother 2005; 39(11):1861-1869.
28. Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, Donohue JF, Sandhaus R. Multi-center study: the biochemical effi cacy, safety and tolerability of a new alpha1- proteinase inhibitor, Zemaira. COPD J 2006; 3:17-23.
29. Healthcare Providers. Augmentation Therapy. http://www. alpha-1foundation.org/healthcare/?c=03a-Augmentation- Therapy. Accessed 3/15/2012.
30. Luisetti M, Miravitlles M, Stockley RA. ?-1-antitrypsin defi ciency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur Respir J 2002; 20:1050-1056.
31. Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003 May; 123(5):1425-1434.
32. Stoller JK, Aboussouan LS. alpha1-Antitrypsin defi ciency. 5: intravenous augmentation therapy: current understanding. Thorax 2004 Aug; 59(8):708-712.